Abstract
In lung cancer, DNA content abnormalities have been described as a heterogeneous spectrum of impaired tumour cell DNA histogram patterns. They are merged into the common term of aneuploidy and probably reflect a high genotypic instability. In non-small-cell lung cancer, the negative effect of aneuploidy has been a subject of controversy inasmuch as studies aimed at determining the survival–DNA content relationship have reported conflicting results. We made a meta-analysis of published studies aimed at determining the prognostic effect of aneuploidy in surgically resected non-small-cell lung cancer. 35 trials have been identified in the literature. A comprehensive collection of data has been constructed taking into account the following parameters: quality of specimen, DNA content assessment method, aneuploidy definition, histology and stage grouping, quality of surgical resection and demographic characteristics of the analysed population. Among the 4033 assessable patients, 2626 suffered from non-small-cell lung cancer with aneuploid DNA content (overall frequency of aneuploidy: 0.65; 95% CI: (0.64–0.67)). The DerSimonian and Laird method was used to estimate the size effects and the Peto and Yusuf method was used in order to generate the odds ratios (OR) of reduction in risk of death for patients affected by a nearly diploid (non-aneuploid) non-small-cell lung cancer. Survivals following surgical resection, from 1 to 5 years, were chosen as the end-points of our meta-analysis. Patients suffering from a nearly diploid tumour benefited from a significant reduction in risk of death at 1, 2, 3 and 4 years with respective OR: 0.51, 0.51, 0.45 and 0.67 (P< 10–4 for each end-point). 5 years after resection, the reduction of death was of lesser magnitude: OR: 0.87 (P = 0.08). The test for overall statistical heterogeneity was conventionally significant (P< 0.01) for all 5 end-points, however. None of the recorded characteristics of the studies could explain this phenomenon precluding a subset analysis. Therefore, the DerSimonian and Laird method was applied inasmuch as this method allows a correction for heterogeneity. This method demonstrated an increase in survival at 1, 2, 3, 4 and 5 years for patients with diploid tumours with respective size effects of 0.11, 0.15, 0.20, 0.20 and 0.21 (value taking into account the correction for heterogeneity; P< 10–4 for each end-point). Patients who benefit from a surgical resection for non-small-cell lung cancer with aneuploid DNA content prove to have a higher risk of death. This negative prognostic factor decreases the probability of survival by 11% at one year, a negative effect deteriorating up to 21% at 5 years following surgery. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Asamura H, Ando M, Matsuno Y and Shimosato Y (1999) Histopathologic prognostic factors in resected adenocarcinomas. Chest 115: 1018–1024
Auer G, Eriksson E, Azavedo E, Caspersson T and Wallgren A (1984) Prognostic significance of nuclear DNA content in mammary adenocarcinomas in humans. Cancer Res 44: 394–396
Barlogie B, Drewinko B, Schumann J, Gohde W, Dosik G, Latreille J, Johnston DA and Freireich EJ (1980) Cellular DNA content as a marker of neoplasia in man. Am J Med 69: 195–203
Barlogie B, Raber MN, Shumann J, Johnson TS, Drewinki B, Swartzendruber DE, Göhde W, Andreeff M and Feireich EJ (1983) Flow cytometry in clinical cancer research. Cancer Res 43: 3982–3997
Blondal T and Bengtsson A (1981) Nuclear DNA measurements in squamous cell carcinoma of the lung: a guide for prognostic evaluation. Anticancer Res 1: 79–86
Bondeson L, Azavedo E, Bondeson AG, Caspersson T and Ljungberg O (1986) Nuclear DNA content and behavior of oxyphil thyroid tumors. Cancer 58: 672–675
Bunn PA, Carney DN, Gazdar AF, Whang-Peng J and Matthews MJ (1983) Diagnostic and biological implications of flow cytometry DNA content analysis in lung cancer. Cancer Res 43: 5026–5032
Carp NZ, Ellison DD, Brophy PF, Watts P, Chang MC and Keller SM (1992) DNA content in correlation with post-surgical stage in non-small-cell lung cancer. Ann Thorac Surg 53: 680–683
Casson AG, McCuaig S, Craig I, Ayed A, Inculet R, Kerkvliet N and O'Malley F (1994) Prognostic value and clinicopathologic correlation of p53 gene mutations and nuclear DNA content in human lung cancer: a prospective study. J Surg Oncol 56: 13–20
Cheon SH, Sohn HY, Chang J, Kim SK, Ko EH, Kim SK, Lee WY, Lee DY, Shin DH, Jeong ET and Chung HT (1993) Flow cytometric analysis of DNA ploidy in primary non-small-cell carcinoma of the lung in Korea. Yonsei Med J 34: 365–370
Chiba W, Sawai S, Hanawa T, Ishida H, Matsui T, Kosaba S, Watanabe S, Hatakenaka R, Matsubara Y, Funatsu T, Ikeda S, Kinoshita M and Matsumoto H (1993) Correlation between DNA content and amplification of oncogenes (c-myc, L-myc, c-erbB-2) and correlation with prognosis in 143 cases of resected lung cancer. Jpn J Cancer Chemother 20: 824–827
Cibas ES, Melamed MR, Zaman MB and Kimmel M (1989) The effect of tumor size and tumor cell DNA content on the survival of patients with stage I adenocarcinoma of the lung. Cancer 63: 1552–1556
Costa A, Silverstrini R, Mochen C, Lequaglie C, Boracchi P, Faranda A, Vessecchia G and Ravasi G (1996) p53 expression, DNA ploidy and S-pase cell fraction in operable locally advanced non-small-cell lung cancer. Br J Cancer 73: 914–919
Coulson BP, Thornthwaite JT, Weelley TW, Sugarbaker EV and Seckinger D (1984) Prognostic indicators including DNA histogram type, receptor content, and staging related to human breast cancer patient survival. Cancer Res 44: 4187–4196
Dalquen P, Moch H, Feichter G, Lehmann M, Solèr M, Stulz P, Jordan P, Torhorst J, Mihatsch MJ and Sauter G (1997) DNA aneuploidy, S-phase fraction, nuclear p53 positivity, and survival in non-small-cell lung carcinoma. Virchows Arch 431: 173–179
Dazzi H, Thatcher N, Hasleton PS and Swindell R (1990) DNA analysis by flow cytometry in non-small-cell lung cancer: relationship to epidermal growth factor receptor, histology, tumour stage and survival. Respir Med 84: 217–223
Del Carlo Bernardi F, Antonangelo L, Beyruti R, Takagaki T, Nascimento Saldiva PH and Capelozzi VL (1997) A prognostic model of survival in surgically resected squamous cell carcinoma of the lung using clinical, pathologic and biologic markers. Mod Pathol 10: 992–1000
DerSimonian R and Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177–188
Filderman AE, Silvestri GA, Gatsonis C, Luthringer DJ, Honig J and Flynn SD (1992) Prognostic significance of tumor proliferative fraction and DNA content in stage I non-small-cell lung cancer. Am Rev Respir Dis 146: 707–710
Friedlander ML, Hedley DW and Taylor IW (1984a) Clinical and biological significance of aneuploidy in human tumours. J clin Pathol 37: 961–974
Friedlander ML, Hedley DW, Taylor IW, Russell P, Coastes AS and Tattersall MHN (1984b) Influence of cellular DNA content on survival in advanced ovarian cancer. Cancer Res 44: 397–400
Granone P, Cardillo G, Rumi E, D'Ugo D, Rumi C, Ciletti S, Margaritora S, Terribile D and Picciocchi A (1993) DNA flow cytometric analysis in patients with operable non-small-cell lung carcinoma. Eur J Cardio-thorac Surg 7: 351–355
Graziano SL, Tatum AH, Gonchoroff NJ, Newman NB and Kohman LJ (1997) Blood group antigen A and flow cytometric analysis in resected early-stage non-small-cell lung cancer. Clin Cancer Res 3: 87–93
Hedley DW, Friedlander ML, Taylor IW, Rugg CA and Musgrove EA (1983) Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem 31: 1333–1335
Huang MS, Colby TV, Therneau TM, Daly RC and Gonchoroff NJ (1996) DNA ploidy and protein content in bronchioloalveolar carcinoma multi-variable flow cytometry. Cytometry 26: 253–259
Ichinose Y, Hara N, Ohta M, Motohiro A, Kuda T and Aso H (1991) Postoperative adjuvant chemotherapy in non-small-cell lung cancer: prognostic value of DNA ploidy and post-recurrent survival. J Surg Oncol 46: 15–20
Ichinose Y, Hara N, Ohta M, Yano T, Maeda K, Asoh H and Katsuda Y (1993) Is T factor of the TNM staging system a predominant prognostic factor in pathologic stage I non-small-cell lung cancer?. J Thorac Cardiovasc Surg 106: 90–94
Ikeda N, McAulay C, Lam S, Garner DM, Payne PW, Kato H, Konaka C and Palcic B (1995) Use of high-resolution cytometry in predicting the biologic behavior of T1 adenocarcinoma of the lung. Analyt Quant Cytol Histol 17: 69–74
Isobe H, Miyamoto H, Shimizu T, Haneda H, Hashimoto M, Inoue K, Mizuno S and Kawakami Y (1990) Prognostic and therapeutic significance of the flow cytometric nuclear DNA content in non-small-cell lung cancer. Cancer 65: 1391–1395
Jeanfaivre T, Chassevent A, Geslin J, Larra F and Tuchais E (1997) Valeur pronostique de la cytometrie en flux dans les cancers bronchiques epidermoides. Etude Retrospective a propos de 61 cas. Bull Cancer 84: 597–602
Kaplan EL and Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481
Kolodziejski L, Niezabitowski A and Gasinska A (1997) Clinical and flow cytometric prognostic factors in surgically treated squamous cell lung cancer. Lung Cancer 16: 173–182
Latreille J, Barlogie B, Dosik G, Johnston DA, Drewinko B and Alexanian R (1980) Cellular DNA content as a marker of human multiple myeloma. Blood 55: 403–408
Liewald F, Hatz R, Storck M, Orend KH, Weiss M, Wulf G, Valet G and Sunder-Plassmann L (1992) prognostic value of deoxyribonucleic acid aneuploidy in primary non-small-cell lung carcinomas and their metastases. J Thorac Cardiovasc Surg 104: 1476–1482
Lima C, Matsui K, Kitagawa M, Mizushima Y, Noto H and Miwa A (1993) Analysis of prognostic factors in patients with resected peripheral T1 adenocarcinoma of the lung. Path Res Pract 189: 1149–1153
Matsura H, Sugimachi K, Ueo H, Kuwano H, Koga Y and Okamura T (1986) Malignant potentiality of squamous cell carcinoma of the esophagus predictable by DNA content. Cancer 57: 1810–1814
Miyamoto H, Harada M, Isobe H, Akita HD, Haneda H, Yamaguchi E, Kuzumaki N and Kawakami Y (1991) Prognostic value of nuclear DNA content and expression of the ras oncogene product in lung cancer. Cancer Res 51: 6346–6350
Mizumoto T, Tokui T, Kusagawa H, Sato T, Wada K, Den T, Kimura M, Namikawa S and Kusagawa M (1991) DNA analysis of resected pulmonary adenocarcinoma. Nippon Kyobu Geka Gakkai Zasshi 39: 1870–1875
Morkve O, Halvorsen OJ, Skjaerven R, Stangeland L, Gulsvik A and Laerum OD (1993) Prognostic significance of p53 protein expression and DNA ploidy in surgically treated non-small-cell lung carcinomas. Anticancer Res 13: 571–578
Muguerza JM, Diez M, Torres AJ, Lopez-Asenjo JA, Picardo AL, Gomez A, Hernando F, Cayon R, Granell J and Balibrea JL (1997) Prognostic value of flow cytometric DNA analysis in non-small-cell lung cancer: rationale of sequential processing of frozen and paraffin-embedded tissue. World J Surg 21: 323–329
Nagai S, Chiba W, Ikeda S, Matsumoto H, Fujimoto T, Ishida H, Wazawa H, Hanawa T, Yamashita N, Yasuda Y, Matsubara Y, Hatakenaka R and Funatsu T (1996) Flow cytometric analysis of the DNA content of resected non-small-cell lung cancer with reference to long–term follow-up. Jpn J Cancer Chemother 23: 130–134
Nicolson GL (1987) Tumor cell instability, diversification, and progression to the metastatic phenotype: from oncogene to oncofetal expression. Cancer Res 47: 1473–1487
Ogawa JI, Iwazaki M, Tsurumi T, Inoue H and Shohtsu A (1991) Prognostic implications of DNA histogram, DNA content, and histologic changes of regional lymph nodes in patients with lung cancer. Cancer 67: 1370–1376
Ogawa JI, Tsurumi T, Inoue H and Shohtsu A (1992) Relationship between tumor DNA ploidy and regional lymph node changes in lung cancer. Cancer 69: 1688–1695
Oud PS, Pahlplatz MMM, Beck JLM, Wiersma–Van Tilburg A, Wagenaar SJ and Vooijs GP (1989) Image and flow cytometry of small cell carcinoma of the lung. Cancer 64: 1304–1309
Pence JC, Kerns BJM, Dodge RK and Iglehart JD (1993) Prognostic significance of the proliferation index in surgically resected non-small-cell lung cancer. Arch Surg 128: 1382–1390
Pujol JL, Simony J, Jolimoy G, Jaffuel D, Demoly P, Quantin X, Marty-Ane C, Boher JM, Charpentier R and Michel FB (1996) Hypodiploidy, Ki-67 growth fraction and prognosis of surgically resected lung cancers. Br J Cancer 74: 964–970
Rice TW, Bauer TW, Gephardt GN, Medendorp SV, McLain DA and Kirby TJ (1993) Prognostic significance of flow cytometry in non-small-cell lung cancer. J Thorac Cardiovasc Surg 106: 210–217
Roberts HL, Komaki R, Allen P and EI-Naggar AK (1998) Prognostic significance of DNA content in stage I adenocarcinoma of the lung. Int J Radiation Oncology Biol Phys 41: 573–578
Sahin AA, Ro JY, EI-Naggar AK, Lee JS, Ayala AG, Teague K and Hong WK (1990) Flow cytometric analysis of the DNA content of non-small-cell lung cancer. Cancer 65: 530–537
Salvati F, Teodori L, Gagliardi L, Signora M, Aquilini M and Storniello G (1989) DNA flow cytometric studies of 66 human lung tumors analyzed before treatment. Prognostic implications. Chest 96: 1092–1098
Salvati F, Teodori L, Trinca ML, Pasquali-Lasagni R and Gohde W (1994) The relevance of flow-cytometric DNA content in the evaluation of lung cancer. J Cancer Res Clin Oncol 120: 233–239
Sara A and EI-Naggar AK (1991) Intratumoral DNA content variability: a study of non-small-cell lung cancer. Am J Clin Pathol 96: 311–317
Shimizu J, Watanabe Y, Oda M, Hayashi Y, Ota Y, Morita K and Arano Y (1993) Results of surgical treatment of stage I lung cancer. Nippon Geka gakkai Zasshi 94: 505–510
Shimosato Y, Asamura H, Yoshida K, Noguchi M, Nakajima T and Mukai K (1989) Factors possibly affecting the degree of malignancy in adenocarcinoma of the lung. DNA content and Bromodeoxyuridine (Brdu) labeling index. Chest S96: 37–38
Shiota T, Konishi T, Kosaba S, Mitsuoka A, Matsubara Y, Hatakenaka R, Funatsu T, Ikeda S, Matsumoto H and Ishigami F (1990) Flow cytometric analysis of cellular DNA content of lung cancer with reference to survival. Nippon Kyobu Geka Gakkai Zasshi 38: 2364–2369
Simony J, Pujol JL, Radal M, Ursule E, Michel FB and Pujol H (1990) In situ evaluation of growth fraction determined by monoclonal antibody Ki-67 and ploidy in surgically resected non-small-cell lung cancers. Cancer Res 50: 4382–4387
Smith L, Barlogie B and Alexanian R (1986) Biclonal and hypodiploid multiple myeloma. Am J Med 80: 841–843
Stewart LA and Parmar MK (1993) Meta-analysis of the literature or of individual patient data: is there a difference?. Lancet 341: 418–422
Stipa S, Tirenidelli-Danesi D, Modini C, Cicconetti F, Mauro F, Schillici A, Mecozzi A, Nicolanti V, Stipa F, Mancini M, Bangrazi C and Botti C (1993) The importance of heterogeneity and of multiple site sampling in the prospective determination of deoxyribonucleic acid flow cytometry. Surg Gynecol Obstet 176: 427–434
Tanaka I, Masuda R, Furuhata Y, Inoue M, Fujiwara M and Takemura T (1995) Flow cytometric analysis of the DNA content of adenocarcinoma of the lung, especially for patients with stage I disease with long term follow-up. Cancer 75: 2461–2465
Ten Velde GPM, Schutte B, Vermeulen A, Volovics A, Reynders MMJ and Blijham GH (1988) Flow cytometric analysis of DNA ploidy level in paraffin-embedded tissue of non-small-cell lung cancer. Eur J Cancer Clin Oncol 24: 455–460
Tirindelli-Danesi D, Teodori L, Mauro F, Modini C, Botti C, Cicconetti F and Stipa S (1987) Prognostic significance of flow cytometry in lung cancer. A 5-year study. Cancer 60: 844–851
Usuda K, Saito Y, Aikawa H, Sakurada A, Chen Y, Takahashi S, Kanma K, Sato M, Sagawa M and Fujimura S (1994) Flow cytometric analysis of nuclear DNA content of lung cancer. Correlation between nuclear DNA content and tumor doubling time. J Jpn Assn Thorac Surg 42: 486–491
Van Bodegom PC, Baak JPA, Stroet-Van Galen C, Schipper NW, Wisse-Brekelmans ECM, Vanderschueren RGJRA and Wagenaar SS (1989) The percentage of aneuploidy cells is significantly correlated with survival in accurately staged patients with stage 1 resected squamous cell lung cancer and long term follow-up. Cancer 63: 143–147
Visakorpi T, Holli K and Hakama M (1995) High cell proliferation activity determined by DNA flow cytometry and prognosis in epidermoid lung carcinoma. Acta Oncol 34: 605–609
Volm M, Bak M, Hanh EW, Mattern J and Weber E (1988a) DNA and S-phase distribution and incidence of metastasis in human primary lung carcinoma. Cytometry 9: 183–188
Volm M, Hahn EW, Mattern J, Muller T, Vogt-Moykopf I and Weber E (1988b) Five-year follow-up study of independent clinical and flow cytometric prognostic factors for the survival of patients with non-small-cell lung carcinoma. Cancer Res 48: 2923–2928
Wolley RC, Schreiber K, Koss LG, Karas M and Sherman A (1982) DNA distribution in human colon carcinomas and its relationship to clinical behavior. J Nat Cancer Inst 69: 15–22
Yamaoka N, Uchiyama Y, Kimino K, Akamine S, Matsuo S and Tsuji K (1989) The prognostic significance of nuclear DNA content in non-small-cell lung carcinoma. Nippon Geka Gakkai Zasshi 91: 1608–1616
Yu J, Shaeffer J, Zhu A, Kuban DA, EI-Mahdi AM and Philput CB (1993) Flow cytometric DNA content and clinical outcome in patients with non-small-cell lung cancer given postoperative radiation therapy. Cytometry 14: 428–432
Yusuf S, Cellins R, Peto R, Furberg C, Stampfer MJ, Goldhaber SZ and Hennekens CH (1985) Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results in mortality, reinfarction and side effects for 33 randomised clinical trials. Eur Heart J 6: 556–585
Zimmerman PV, Bint MH, Hawson GAT and Parsons PG (1987) Ploidy as a prognostic determinant in surgically treated lung cancer. Lancet 2: 530–533
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Choma, D., Daurès, JP., Quantin, X. et al. Aneuploidy and prognosis of non-small-cell lung cancer: a meta-analysis of published data. Br J Cancer 85, 14–22 (2001). https://doi.org/10.1054/bjoc.2001.1892
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.1892
Keywords
This article is cited by
-
Disentangling the roles of aneuploidy, chromosomal instability and tumour heterogeneity in developing resistance to cancer therapies
Chromosome Research (2023)
-
Clinical Value of EGFR Copy Number Gain Determined by Amplicon-Based Targeted Next Generation Sequencing in Patients with EGFR-Mutated NSCLC
Targeted Oncology (2021)
-
Prognostic value of DNA aneuploidy in gastric cancer: a meta-analysis of 3449 cases
BMC Cancer (2019)
-
Determinants and clinical implications of chromosomal instability in cancer
Nature Reviews Clinical Oncology (2018)
-
Prolonged pemetrexed pretreatment augments persistence of cisplatin-induced DNA damage and eliminates resistant lung cancer stem-like cells associated with EMT
BMC Cancer (2016)